To avoid overfitting and prove true generalization, Bolts validates its protein design models by testing them across a wide array of targets from over 25 external academic and industry labs. This diverse, real-world testing is the ultimate benchmark of a model's utility in drug discovery.

To maximize advantages, an in-house lab consciously selected a different NGS testing platform than major external vendors. This strategic choice not only reduced tissue sample requirements but also offered a faster turnaround time due to the underlying technology, creating a distinct competitive advantage beyond mere proximity.

To ensure patients get the same result from any test provider, the field must standardize not just the underlying sequencing technology, but also the software pipelines for data analysis and the clinical frameworks for interpreting results. Each layer presents a unique harmonization challenge.

For certain therapies like Enhertu, eligibility is based on immunohistochemistry (IHC), not NGS. Labs must run HER2 IHC in parallel because NGS, as a population-based test, can miss intratumoral heterogeneity (small clusters of positive cells) that IHC can detect, thus identifying more eligible patients for targeted therapy.

To overcome logistical delays, a hybrid lab testing model is effective. It uses local labs for rapid eligibility screening to accelerate patient enrollment, while simultaneously using central labs for standardized, confirmatory validation. This approach balances the need for speed with the requirement for rigorous, reliable data.

A key advantage of in-house genomic assays, like MSK's, is the ability to rapidly iterate based on direct feedback from practicing clinicians. This agile development cycle allows the test to be continuously updated with new genes and regions of interest, keeping it at the cutting edge of clinical and research needs.

When the FDA approves a new biomarker-linked therapy, an in-house pathology lab actively queries its historical database of all prior NGS tests to identify past cases with the relevant genetic alteration. They then proactively contact the oncologists for these patients, uncovering new treatment options that were previously unavailable.

When running multiple independent but parallel experiments, include well-characterized compounds in every group. These "anchor compounds" serve as internal calibration references, creating a baseline that allows for robust and reliable comparison of results across the otherwise separate experimental sets.

Outpost Bio integrates a wet lab with its AI platform to generate proprietary, high-quality data. This is crucial in microbiology, where reproducibility is a challenge. This vertical integration creates a "gold standard" dataset for model training and allows for experimental validation of AI-driven predictions in a closed loop.